Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)

David Goodman-Meza,Steven Shoptaw,Brett Hanscom,Laramie R. Smith,Philip Andrew,Irene Kuo,Jordan E. Lake,David Metzger,Ellen A. B. Morrison,Melissa Cummings,Jessica M. Fogel,Paul Richardson,Jayla Harris,Jesse Heitner,Sarah Stansfield,Nabila El-Bassel,for the HPTN 094 Study Team
DOI: https://doi.org/10.1186/s13063-023-07899-5
IF: 2.728
2024-02-17
Trials
Abstract:Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including medication for opioid use disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), and testing and treatment for sexually transmitted infections (STIs). Most services, when available, including those that address substance misuse, HIV prevention, and STIs, are often provided in multiple locations that may be difficult to access, which further challenges sustained health for PWID. HPTN 094 (INTEGRA) is a study designed to test the efficacy of an integrated, "whole-person" strategy that provides integrated HIV prevention including antiretroviral therapy (ART), PrEP, MOUD, and STI testing and treatment from a mobile health delivery unit ("mobile unit") with peer navigation compared to peer navigation alone to access these services at brick and mortar locations.
medicine, research & experimental
What problem does this paper attempt to address?